ArticleBiosensors2025
High-Precision Field- Effect Transistor Biosensor for Analyzing Differential Effects of Anti-Cancer Drugs on Cancerous and Non-Cancerous Cells.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A high-precision biosensor technique is introduced, offering the capability to independently evaluate the effects of anti-cancer drugs on both cancerous (RAJI) and non-cancerous (WIL2S) cells. By analyzing and fitting current change curves and transfer characteristic curves under two drugs, camptothecin and doxorubicin, this technique quantifies both the magnitude of drug-induced current changes in cells and the rate of drug entry into cells. Flow cytometry was utilized to validate the entry rates of two drugs, camptothecin and doxorubicin, into the cells. The biosensor leverages the exceptional sensitivity of two-dimensional electron gas to detect proximal charge variations at ultralow concentrations, even in fluids with high ionic strength. The findings reveal that anti-cancer drugs have a more pronounced impact on tumor cells, with the effects and interaction speeds differing across normal cells and tumor cells. This innovative approach not only enhances our understanding of the specificity and action mechanisms of anti-cancer drugs but also provides a valuable tool for screening potential tumor anti-cancer drugs and advancing targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.